Your browser is no longer supported. Please, upgrade your browser.
ImmunoGen, Inc.
Index- P/E- EPS (ttm)-0.41 Insider Own0.10% Shs Outstand194.71M Perf Week3.30%
Market Cap1.42B Forward P/E- EPS next Y-0.77 Insider Trans-5.31% Shs Float176.17M Perf Month-3.09%
Income-70.90M PEG- EPS next Q-0.10 Inst Own73.60% Short Float12.94% Perf Quarter31.81%
Sales91.40M P/S15.54 EPS this Y41.80% Inst Trans-0.02% Short Ratio8.80 Perf Half Y55.39%
Book/sh-0.25 P/B- EPS next Y-40.00% ROA-27.00% Target Price9.44 Perf Year49.28%
Cash/sh0.96 P/C7.55 EPS next 5Y- ROE192.20% 52W Range1.95 - 7.87 Perf YTD11.78%
Dividend- P/FCF- EPS past 5Y0.10% ROI124.60% 52W High-8.39% Beta1.48
Dividend %- Quick Ratio2.20 Sales past 5Y-0.80% Gross Margin- 52W Low269.74% ATR0.39
Employees75 Current Ratio2.20 Sales Q/Q36.80% Oper. Margin-55.10% RSI (14)57.55 Volatility5.08% 5.30%
OptionableYes Debt/Eq- EPS Q/Q12.50% Profit Margin-77.70% Rel Volume0.79 Prev Close7.58
ShortableYes LT Debt/Eq- EarningsNov 06 BMO Payout- Avg Volume2.59M Price7.21
Recom2.10 SMA203.06% SMA5012.76% SMA20049.83% Volume2,032,979 Change-4.88%
Oct-26-20Resumed H.C. Wainwright Buy $11
Oct-02-20Upgrade Guggenheim Neutral → Buy $14
Sep-29-20Resumed JP Morgan Neutral
Dec-17-19Reiterated H.C. Wainwright Buy $5 → $9
Aug-13-19Reiterated H.C. Wainwright Buy $4 → $5
May-15-19Downgrade Guggenheim Buy → Neutral
May-06-19Upgrade H.C. Wainwright Neutral → Buy $7
May-06-19Upgrade Cowen Market Perform → Outperform
Mar-19-19Downgrade JP Morgan Neutral → Underweight
Mar-05-19Upgrade Morgan Stanley Underweight → Equal-Weight
Mar-04-19Downgrade SVB Leerink Outperform → Mkt Perform
Mar-04-19Downgrade H.C. Wainwright Buy → Neutral $18 → $3.50
Mar-01-19Downgrade Piper Jaffray Overweight → Neutral $13 → $2.50
Mar-01-19Downgrade Jefferies Buy → Hold
Sep-07-18Initiated Piper Jaffray Overweight
Feb-08-18Resumed RBC Capital Mkts Outperform $12
Jan-31-18Initiated H.C. Wainwright Buy $18
Jul-06-17Upgrade RBC Capital Mkts Sector Perform → Outperform $5 → $12
Apr-19-17Upgrade Leerink Partners Mkt Perform → Outperform
Apr-29-16Downgrade RBC Capital Mkts Outperform → Sector Perform $18 → $7
Jan-04-21 04:30PM  
Dec-30-20 04:30PM  
Dec-26-20 03:58AM  
Dec-16-20 03:20PM  
Dec-06-20 11:30AM  
Dec-05-20 03:01PM  
Dec-01-20 04:30PM  
Nov-30-20 04:30PM  
Nov-18-20 04:30PM  
Nov-11-20 06:33AM  
Nov-10-20 06:23AM  
Nov-09-20 09:56AM  
Nov-06-20 12:30PM  
Nov-05-20 10:10AM  
Nov-04-20 04:30PM  
Nov-02-20 04:30PM  
Oct-30-20 12:30PM  
Oct-29-20 10:58AM  
Oct-22-20 04:01PM  
Oct-20-20 10:56AM  
Oct-19-20 08:45AM  
Oct-12-20 01:26PM  
Oct-06-20 12:57PM  
Oct-05-20 09:52AM  
Oct-01-20 04:30PM  
Sep-17-20 03:01AM  
Sep-14-20 12:20PM  
Sep-02-20 04:30PM  
Sep-01-20 04:30PM  
Aug-30-20 11:30AM  
Aug-04-20 11:14AM  
Aug-03-20 04:30PM  
Jul-31-20 07:03PM  
Jul-29-20 04:30PM  
Jul-27-20 01:08PM  
Jul-24-20 12:30PM  
Jul-22-20 08:00AM  
Jul-20-20 07:00AM  
Jul-16-20 04:01PM  
Jul-14-20 05:31PM  
Jun-23-20 09:42PM  
Jun-22-20 09:01AM  
Jun-03-20 08:00AM  
Jun-02-20 08:00AM  
Jun-01-20 08:00AM  
May-31-20 11:30AM  
May-29-20 08:01AM  
May-20-20 10:04PM  
May-19-20 04:08PM  
May-15-20 12:01AM  
May-13-20 05:01PM  
May-06-20 04:30PM  
May-05-20 07:55AM  
May-04-20 04:17PM  
May-01-20 01:31PM  
Apr-24-20 12:30PM  
Apr-16-20 04:01PM  
Mar-15-20 11:30AM  
Feb-21-20 10:17AM  
Feb-18-20 08:35AM  
Feb-17-20 09:41AM  
Feb-14-20 05:00PM  
Feb-07-20 12:30PM  
Feb-06-20 04:30PM  
Feb-03-20 04:30PM  
Jan-30-20 04:01PM  
Jan-27-20 04:01PM  
Jan-23-20 07:24AM  
Jan-22-20 08:44PM  
Jan-03-20 10:46AM  
Dec-31-19 04:01PM  
Dec-24-19 07:12AM  
Dec-19-19 12:50PM  
Dec-18-19 08:25AM  
Dec-17-19 04:00PM  
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. Its preclinical program include IMGC936, an investigational ADC in co-development with MacroGenics, Inc. ImmunoGen, Inc. has collaborations with Roche; Amgen/Oxford BioTherapeutics; sanofi-aventis U. S. LLC; Biotest AG; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Fusion Pharmaceuticals Inc.; Debiopharm International SA; Jazz Pharmaceuticals Ireland Limited; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FOSTER DAVID GV.P.-Fin., Prin. Acctg. Off.Dec 31Sale6.3811,05270,51237,912Jan 04 05:32 PM
FOSTER DAVID GV.P.-Fin., Prin. Acctg. Off.Apr 02Sale3.435,44818,68721,382Apr 02 03:56 PM
Ryll ThomasSVP, Technical OperationsFeb 24Sale4.9916,79083,78275,624Feb 25 08:38 AM
Berkenblit AnnaSVP & Chief Medical OfficerFeb 24Sale4.9925,803128,75798,089Feb 25 08:37 AM
Enyedy Mark JChief Executive OfficerFeb 24Sale4.9955,222275,558433,776Feb 25 08:38 AM
BARROWS CRAIGExecutive VP, General CounselFeb 24Sale4.9916,49282,295145,275Feb 25 08:36 AM
Wingrove TheresaSVP of Regulatory AffairsFeb 24Sale4.9916,14780,57470,498Feb 25 08:37 AM